Approximately 4 million people worldwide, especially in the USA and Europe are affected by chronic intestinal bowel disease (IBD),
especially Crohn disease (CD), ulcerative colitis (UC). IBD seem to be a consequence of harmful interactions of the intestinal microbiota,
epithelium and immune system of genetic susceptible persons. Modern molecular analysis has demonstrated that patients with IBD
have a low-diversity distorted intestinal microbiota. The idea of using faeces for a gut microbiota (as opposed to using a
defined bacterial community) is an approach we have right now to treat every patient. However, it is known that there is a large variability
in the gut microbiota from person to person. More research is needed to understand the variability that people exhibit in their microbiota
and how FMT could potentially lead to disease in order to help minimize these unintended consequences.
Last date updated on January, 2021